Search research articles
Contact Us
Filters
Showing results (131-140 of 267) with videos related to
Page
of 27
Sort By:
Journal of Bone Oncology
|
November 19, 2015
Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study
Christina L Addison, Gregory R Pond, Brandy Cochrane, et al.
Clinical Breast Cancer
|
March 21, 2009
Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design
Farrah Kassam, Katherine Enright, Rebecca Dent, et al.
International Journal of Surgical Oncology
|
February 17, 2015
Evaluating the feasibility of performing window of opportunity trials in breast cancer
Angel Arnaout, Susan Robertson, Iryna Kuchuk, et al.
Current Oncology (Toronto, Ont.)
|
July 21, 2021
Does the Time of Day at Which Endocrine Therapy Is Taken Affect Breast Cancer Patient Outcomes?
Ana-Alicia Beltran-Bless, Lisa Vandermeer, Mohammed F K Ibrahim, et al.
Oncology Letters
|
February 15, 2014
Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression
Daniel Khalaf, John F Hilton, Mark Clemons, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
March 11, 2017
A cost-utility analysis of risk model-guided versus physician's choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach
Kednapa Thavorn, Doug Coyle, Jeffrey S Hoch, et al.
Journal of Bone Oncology
|
December 9, 2020
Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey
Mashari AlZahrani, Mark Clemons, Lisa Vandermeer, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
May 6, 2016
Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review
Ricardo Fernandes, Sasha Mazzarello, Brian Hutton, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
January 21, 2022
Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers
Mashari Alzahrani, Carol Stober, Michelle Liu, et al.
Cancers
|
February 11, 2023
Doxycycline-Induced Changes in Circulating MMP or TIMP2 Levels Are Not Associated with Skeletal-Related Event-Free or Overall Survival in Patients with Bone Metastases from Breast Cancer
Huijun Zhao, Gregory Pond, Demetrios Simos, et al.
Page
of 27
Search research articles
Search
Showing results (131-140 of 267) with videos related to
Sort By:
Page
of 27
Journal of Bone Oncology
|
November 19, 2015
Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study
Christina L Addison, Gregory R Pond, Brandy Cochrane, et al.
Clinical Breast Cancer
|
March 21, 2009
Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design
Farrah Kassam, Katherine Enright, Rebecca Dent, et al.
International Journal of Surgical Oncology
|
February 17, 2015
Evaluating the feasibility of performing window of opportunity trials in breast cancer
Angel Arnaout, Susan Robertson, Iryna Kuchuk, et al.
Current Oncology (Toronto, Ont.)
|
July 21, 2021
Does the Time of Day at Which Endocrine Therapy Is Taken Affect Breast Cancer Patient Outcomes?
Ana-Alicia Beltran-Bless, Lisa Vandermeer, Mohammed F K Ibrahim, et al.
Oncology Letters
|
February 15, 2014
Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression
Daniel Khalaf, John F Hilton, Mark Clemons, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
March 11, 2017
A cost-utility analysis of risk model-guided versus physician's choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach
Kednapa Thavorn, Doug Coyle, Jeffrey S Hoch, et al.
Journal of Bone Oncology
|
December 9, 2020
Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey
Mashari AlZahrani, Mark Clemons, Lisa Vandermeer, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
May 6, 2016
Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review
Ricardo Fernandes, Sasha Mazzarello, Brian Hutton, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
January 21, 2022
Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers
Mashari Alzahrani, Carol Stober, Michelle Liu, et al.
Cancers
|
February 11, 2023
Doxycycline-Induced Changes in Circulating MMP or TIMP2 Levels Are Not Associated with Skeletal-Related Event-Free or Overall Survival in Patients with Bone Metastases from Breast Cancer
Huijun Zhao, Gregory Pond, Demetrios Simos, et al.
Page
of 27